Cogstate is pleased to announce the appointment of two new executives who will join our Executive Leadership Team. Mr Darren Watson has been appointed as Chief Financial Officer (CFO) effective 1 February 2021 and Mr Ben Bloomfield has been appointed as Chief Technology Officer (CTO) effective 11 January 2021.
Cogstate is pleased to announce the appointment of Ms Kim Wenn as an Independent Non-Executive Director, effective immediately. Kim brings extensive technology experience and strong commercial expertise to the Board of Cogstate, with over 30 years experience in innovation roles.
Leaders from Cogstate Join the Davos Alzheimer’s Collaborative to Accelerate Innovation and Preparedness for Disease Interventions
Cogstate Ltd announced today that four members of its executive leadership team have joined the Davos Alzheimer’s Collaborative (DAC), a pre-competitive coalition and a 5-year, ~$300 million plan focused on driving global scientific, business, policy and financial coordination in Alzheimer’s disease preparedness.
Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies
Eisai and Cogstate announced that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate for use in healthcare and other markets.
Cogstate announced the appointment of Chris Edgar, PhD as Chief Science Officer and Prof. Paul Maruff, PhD as Chief Innovation Officer. These appointments represent an expansion of the executive leadership team with strengthened scientific capacity as the company continues to meet the growing demand for transformative innovations in clinical trials and healthcare.
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Cogstate Ltd. (ASX: CGS;OTCQX: COGZF), a cognitive science and technology company publicly listed on the Australian Securities Exchange, has qualified to trade on the OTCQX® Best Market. Cogstate Ltd. upgraded to OTCQX from the Pink® market.
ERT Announced Partnership with Cogstate to Expand its eCOA Solution for Higher Fidelity CNS Assessments
ERT, the global leader in clinical endpoint data collection, today announced a preferred partnership with Cogstate to expand its industry-leading electronic Clinical Outcome Assessment (eCOA) solution with digital cognitive endpoints from Cogstate to support the development of treatments for Central Nervous System (CNS) and other disorders.
Cogstate Receives Digital Biomarker Award from ADDF to Develop Mobile App for Early Detection of Memory Impairment
Cogstate today announced an award from the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) initiative, which is a partnership of funders seeking to develop novel biomarkers for the early detection of Alzheimer’s disease and related dementias. The up to $1.3 million award to Cogstate will be focused on the development of a technology-based approach for early detection of memory impairment and decline.
Eisai Co., Ltd (Tokyo) today announced the launch of “NouKNOW”, a digital tool for self-assessment of brain health based upon technology created by Cogstate. The Japanese product launch will occur on 31 March 2020 and will initially target municipalities providing health services to local residents and corporations providing health checks for employees.
Cogstate announced today that Ken Billard has joined the company in the role of Chief Commercial Officer. Ken brings proven expertise in sales leadership and strategic partnering to Cogstate, where he will oversee the global sales organization to develop and execute strategies focused on expanding the adoption of Cogstate solutions in pharmaceutical clinical trials.
Eisai Enters Into Business Alliance with Cogstate for Exclusive Development and Commercialization of a Digital Tool for Self-Assessment of Cognitive Function in Japan
Eisai entered into a business alliance agreement with Cogstate for exclusive development and commercialization of a cognitive function test, the Cogstate Brief Battery (CBB), in Japan as a digital tool for self-assessment of cognitive function.
Cogstate today announced a presentation entitled, “Methodology for Development of Indication-Specific Outcome Measures in Rare Disease Trials: An Innovative Research Approach” will be delivered at the National Organization for Rare Diseases (NORD) Rare Disease Summit in Washington, D.C.